Platelets protect vascular integrity during inflammation. Recent evidence suggests that this action is independent of thrombus formation and requires the engagement of glycoprotein VI (GPVI), but it remains unclear how platelets prevent inflammatory bleeding. We investigated whether platelets and GPVI act primarily by preventing detrimental effects of neutrophils using models of immune complex (IC)-mediated inflammation in mice immunodepleted in platelets and/or neutrophils or deficient in GPVI. Depletion of neutrophils prevented bleeding in thrombocytopenic and GPVI(-/-) mice during IC-mediated dermatitis. GPVI deficiency did not modify neutrophil recruitment, which was reduced by thrombocytopenia. Neutrophil cytotoxic activities were reduced in thrombocytopenic and GPVI(-/-) mice during IC-mediated inflammation. Intravital microscopy revealed that in this setting, intravascular binding sites for platelets were exposed by neutrophils, and GPVI supported the recruitment of individual platelets to these spots. Furthermore, the platelet secretory response accompanying IC-mediated inflammation was partly mediated by GPVI, and blocking of GPVI signaling impaired the vasculoprotective action of platelets. Together, our results show that GPVI plays a dual role in inflammation by enhancing neutrophil-damaging activities while supporting the activation and hemostatic adhesion of single platelets to neutrophil-induced vascular breaches.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2014-12-617159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.
Nat Cardiovasc Res
December 2024
NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Article Synopsis
- Immune checkpoint inhibitor (ICI) therapies used in cancer treatment may elevate the risk of heart-related issues in cancer survivors by worsening atherosclerosis, a condition affecting artery health.
- Researchers have identified a network of immune cell interactions within atherosclerotic plaques that can be targeted by ICIs, where a specific group of dendritic cells plays a significant role in immune signaling.
- The study also indicates that factors like type 2 diabetes and lipid-lowering medications can alter how immune cells interact, potentially affecting plaque inflammation and highlighting the need for strategies to reduce heart disease risk in patients undergoing ICI treatments.
Structural properties of immune complexes formed by viral antigens and specific antibodies shape the inflammatory response of macrophages.
Cell Biosci
April 2024
Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio Ave. 7, 10257, Vilnius, Lithuania.
Data on the course of viral infections revealed severe inflammation as a consequence of antiviral immune response. Despite extensive research, there are insufficient data on the role of innate immune cells in promoting inflammation mediated by immune complexes (IC) of viral antigens and their specific antibodies. Recently, we demonstrated that antigens of human polyomaviruses (PyVs) induce an inflammatory response in macrophages.
View Article and Find Full Text PDFIgG immune complex-induced acute lung injury is ameliorated by cAMP via down-regulation of C/EBP- and AP-1-mediated transcriptions.
J Inflamm (Lond)
October 2023
Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine for Acute Abdominal Diseases, Integrated Chinese and Western Medicine Hospital, Tianjin University, Tianjin, 300100, China.
Background: Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS) are life threatening pulmonary diseases, and we are now lack of effective therapeutic methods. Inflammatory responses are essential for initiating ALI/ARDS. Thus, ameliorating inflammatory reaction might be beneficial for treatment of the disease.
View Article and Find Full Text PDFLuteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activation and dermal-epidermal separation in an model of epidermolysis bullosa acquisita.
Front Immunol
September 2023
Priority Area Chronic Lung Diseases, Research Center Borstel, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germany.
Introduction: Natural products have been shown to an important source of therapeutics for human disease. In this study, we aimed to identify natural compounds as potential therapeutics for epidermolysis bullosa acquisita (EBA), an autoimmune disease caused by autoantibodies to type VII collagen (COL7).
Methods: Utilizing an experimental system, we screened a natural product library composed of 800 pure compounds for their inhibitory effect on COL7-anti-COL7 IgG immune complex (IC)-mediated neutrophil activation and on neutrophil-mediated tissue damage.
Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.
Front Immunol
May 2023
Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Article Synopsis
- Biologics are crucial in treating various diseases but can cause adverse events due to immunogenicity from large immune complexes, raising concerns about injection site reactions (ISRs).
- Ozoralizumab, a unique bispecific NANOBODY, shows promise for rheumatoid arthritis treatment with a low ISR rate (only 2%) and good safety profiles compared to traditional TNFα inhibitors like adalimumab.
- The study indicates that ozoralizumab-TNFα immune complexes are smaller and lack an Fc portion, reducing inflammatory immune responses and suggesting a safer option for RA management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!